Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,738 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Failure Chronic Clear all
Completed No phase listed Observational

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

NCT01282762
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

NCT01788046
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
45
States / cities
Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

NCT01680861
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 25, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional

Effects of Replacing High Protein Foods in People With Chronic Kidney Disease

NCT07105670
View directory record Official record
Conditions
Chronic Kidney Disease Stage 3
Interventions
Controlled dietary intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Results available

The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study

NCT01102140
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
POMx, pomegranate polyphenol extract, Sugar Pill
Drug
Lead sponsor
Jennifer Cowger , MD, MS
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 25, 2026, 4:38 PM EDT
Active, not recruiting Phase 4 Interventional

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

NCT03982160
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
L-Arginine, Placebo
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
35 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Newark, Delaware • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

NCT05213624
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Active, not recruiting No phase listed Observational

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

NCT03615235
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • San Francisco, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional

Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)

NCT07211035
View directory record Official record
Conditions
End Stage Kidney Disease (ESRD)
Interventions
The Amplifi System is a temporary extracorporeal blood pump designed to deliver controlled flow through a peripheral vein for 24-72 hours prior to AVF creation., Standard of Care (AVF creation)
Device · Procedure
Lead sponsor
Amplifi Vascular, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Not applicable Interventional

House Calls and Decision Support: Improving Access to Live Donor Transplantation

NCT01786525
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
House Calls, Web-Based Patient-Centered Decision Support Intervention
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 25, 2026, 4:38 PM EDT
Not listed Phase 4 Interventional

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

NCT01731301
View directory record Official record
Conditions
Chronic Hepatitis C, End Stage Renal Disease
Interventions
Ribavirin, Peginterferon, Boceprevir
Drug
Lead sponsor
Liver Institute of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 25, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional

Chronic Kidney Disease-Education (CKD-EDU)

NCT06410144
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Program A, Program B
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
75 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Brockport, New York • Canandaigua, New York • Hornell, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Not applicable Interventional

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

NCT05879302
View directory record Official record
Conditions
End Stage Renal Disease, End-Stage Kidney Disease, Kidney Transplantation, Esrd
Interventions
Kidney Offer Shared Decision Making
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04471337
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

NCT04736628
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Avenciguat, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Canyon Country, California • Rancho Cucamonga, California • Victorville, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study

NCT01768637
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

NCT04484857
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Not applicable Interventional

iChoose Decision Kidney Aid for End-Stage Renal Disease Patients

NCT02235571
View directory record Official record
Conditions
End-Stage Kidney Disease, Kidney Failure, Chronic, Kidney Transplantation
Interventions
iChoose Kidney Decision Aid
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Not applicable Interventional

Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation

NCT02342119
View directory record Official record
Conditions
End-stage Kidney Disease
Interventions
Talking About Living Kidney Donation, Kidney Transplant Fast Track
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 25, 2026, 4:38 PM EDT
Completed No phase listed Observational

Transplant Patient Registry of Liver, Kidney and/or Pancreas

NCT00238693
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Liver Disease
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
13,767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Not applicable Interventional Results available

Premarket Clinical Safety Assessment of the ELISIO™-HX

NCT07058909
View directory record Official record
Conditions
Renal Failure, Acute Renal Failure, Chronic Renal Failure, Chronic Kidney Diseases, End Stage Renal Disease
Interventions
ELISIO™-HX Dialyzer
Device
Lead sponsor
Nipro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional

Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients

NCT04163614
View directory record Official record
Conditions
End Stage Renal Disease, Hypertension, Extracellular Volume Overload, Intradialytic Hypotension
Interventions
IBPS-Guided Ultrafiltration
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

NCT02837237
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 25, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

NCT03386539
View directory record Official record
Conditions
Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions
Everolimus, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 4:38 PM EDT